News & Events
- Seres Therapeutics Announces Receipt of Expected $50 Million Installment Payment Related to VOWST Sale
- Seres Therapeutics Announces New Translational Biomarker Results from SER-155 Phase 1b Clinical Study and Provides Corporate Updates
- GENETIC ANALYSIS AND FERRING PHARMACEUTICALS ANNOUNCE A COLLABORATION TO DEVELOP A NEW MICROBIOME RAPID DIAGNOSTIC TEST
- Seres Therapeutics to Participate in 2025 J.P. Morgan Healthcare Conference
- FDA Grants Breakthrough Therapy Designation to Seres Therapeutics’ SER-155 for Reduction of Bloodstream Infections in Adults Undergoing Allogeneic Hematopoietic Stem Cell Transplant (allo-HSCT)
- Seres Therapeutics to Participate in Piper Sandler Healthcare Conference
- Publication of Q3 Interim Report January – September 2024
- Genetic Analysis AS: Interim report January – September 2024
- Seres Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Updates
- Seres Therapeutics to Announce Third Quarter 2024 Financial Results and Business Updates on November 13, 2024
- Vedanta Biosciences To Present at IDWeek 2024 on Benefit of VE303 on Antibiotic Resistant Gene Levels in Patient Microbiomes
- Seres Therapeutics Announces Completion of VOWST™ Asset Sale to Société des Produits Nestlé S.A
- Seres Therapeutics Stockholders Approve Sale of VOWST™ to Nestlé Health Science; Sale Expected to Close on September 30
- Seres Therapeutics to Participate in Cantor 2024 Global Healthcare Conference
- Seres Therapeutics Reports SER-155 Phase 1b Placebo-Controlled Cohort 2 Study Safety and Clinical Results in Patients Undergoing Allogeneic Hematopoietic Stem Cell Transplant (allo-HSCT)